CN102532159B - Small molecule inhibitors Syntelin for centromere-associated protein E (CENP-E) - Google Patents
Small molecule inhibitors Syntelin for centromere-associated protein E (CENP-E) Download PDFInfo
- Publication number
- CN102532159B CN102532159B CN201110356727.XA CN201110356727A CN102532159B CN 102532159 B CN102532159 B CN 102532159B CN 201110356727 A CN201110356727 A CN 201110356727A CN 102532159 B CN102532159 B CN 102532159B
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- syntelin
- cenp
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- SPRISILOMIVCIR-UHFFFAOYSA-N 2-[[5-[(4-amino-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-2-yl)sulfanylmethyl]-4-phenyl-1,2,4-triazol-3-yl]sulfanyl]acetic acid Chemical compound N=1C=2SC=3CCCCC=3C=2C(N)=NC=1SCC1=NN=C(SCC(O)=O)N1C1=CC=CC=C1 SPRISILOMIVCIR-UHFFFAOYSA-N 0.000 title abstract description 83
- 102100025832 Centromere-associated protein E Human genes 0.000 title abstract description 75
- 101710105881 Centromere-associated protein E Proteins 0.000 title abstract description 75
- 239000003112 inhibitor Substances 0.000 title abstract description 13
- 150000003384 small molecules Chemical class 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 90
- 238000000034 method Methods 0.000 claims description 45
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 40
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 36
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 29
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 20
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 15
- 238000001953 recrystallisation Methods 0.000 claims description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 14
- 238000005406 washing Methods 0.000 claims description 14
- 239000003960 organic solvent Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000003513 alkali Substances 0.000 claims description 10
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 235000015320 potassium carbonate Nutrition 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 10
- 230000006870 function Effects 0.000 abstract description 8
- 210000000349 chromosome Anatomy 0.000 abstract description 6
- 230000000394 mitotic effect Effects 0.000 abstract description 6
- 230000004663 cell proliferation Effects 0.000 abstract description 3
- 210000004881 tumor cell Anatomy 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 61
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 55
- 102000029749 Microtubule Human genes 0.000 description 35
- 108091022875 Microtubule Proteins 0.000 description 35
- 210000004688 microtubule Anatomy 0.000 description 35
- 230000008569 process Effects 0.000 description 24
- 238000000967 suction filtration Methods 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 23
- 238000003786 synthesis reaction Methods 0.000 description 23
- 238000011282 treatment Methods 0.000 description 22
- 108020004459 Small interfering RNA Proteins 0.000 description 21
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 238000012544 monitoring process Methods 0.000 description 14
- 229960001701 chloroform Drugs 0.000 description 13
- 229930012538 Paclitaxel Natural products 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 108010013043 Acetylesterase Proteins 0.000 description 10
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 10
- 230000006837 decompression Effects 0.000 description 10
- 238000013461 design Methods 0.000 description 10
- 239000003226 mitogen Substances 0.000 description 10
- 229960001592 paclitaxel Drugs 0.000 description 10
- 238000011084 recovery Methods 0.000 description 10
- 238000004064 recycling Methods 0.000 description 10
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 10
- 238000001816 cooling Methods 0.000 description 9
- 230000002759 chromosomal effect Effects 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 238000001890 transfection Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 108060001084 Luciferase Proteins 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 210000002415 kinetochore Anatomy 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 230000021572 chromosome movement towards spindle pole Effects 0.000 description 4
- 239000006059 cover glass Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000012124 Opti-MEM Substances 0.000 description 3
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 3
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000012151 immunohistochemical method Methods 0.000 description 3
- 230000037023 motor activity Effects 0.000 description 3
- 230000007659 motor function Effects 0.000 description 3
- 229940049547 paraxin Drugs 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- LOBCDGHHHHGHFA-LBPRGKRZSA-N (S)-monastrol Chemical compound CCOC(=O)C1=C(C)NC(=S)N[C@H]1C1=CC=CC(O)=C1 LOBCDGHHHHGHFA-LBPRGKRZSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000037051 Chromosomal Instability Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000031016 anaphase Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000012930 cell culture fluid Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 210000002230 centromere Anatomy 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 230000005311 nuclear magnetism Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 150000004579 taxol derivatives Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 1
- KPPVNWGJXFMGAM-UUILKARUSA-N (e)-2-methyl-1-(6-methyl-3,4-dihydro-2h-quinolin-1-yl)but-2-en-1-one Chemical compound CC1=CC=C2N(C(=O)C(/C)=C/C)CCCC2=C1 KPPVNWGJXFMGAM-UUILKARUSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- CDYVTVLXEWMCHU-UHFFFAOYSA-N CCOC(c1c(N)[s]c2c1CCCC2)=O Chemical compound CCOC(c1c(N)[s]c2c1CCCC2)=O CDYVTVLXEWMCHU-UHFFFAOYSA-N 0.000 description 1
- GWODVUCCBIQPDW-UHFFFAOYSA-N CCOC(c1c(NC(N)=O)[s]c2c1CCCC2)=O Chemical compound CCOC(c1c(NC(N)=O)[s]c2c1CCCC2)=O GWODVUCCBIQPDW-UHFFFAOYSA-N 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 102000010638 Kinesin Human genes 0.000 description 1
- 108010063296 Kinesin Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 1
- 101150008132 NDE1 gene Proteins 0.000 description 1
- FLBUBMOKRJJLKX-UHFFFAOYSA-N O=C(c1c(N2)[s]c3c1CCCC3)NC2=O Chemical compound O=C(c1c(N2)[s]c3c1CCCC3)NC2=O FLBUBMOKRJJLKX-UHFFFAOYSA-N 0.000 description 1
- MMKATEASKWNFEM-UHFFFAOYSA-N O=S[ClH]C1CC1 Chemical compound O=S[ClH]C1CC1 MMKATEASKWNFEM-UHFFFAOYSA-N 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003322 aneuploid effect Effects 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000000609 carbazolyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000004718 centriole Anatomy 0.000 description 1
- 210000003793 centrosome Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 1
- 230000024321 chromosome segregation Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000019130 spindle checkpoint Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses small molecule inhibitors Syntelin for centromere-associated protein E (CENP-E). The inhibitors have the structural formula I or II. The inhibitors have functions of inhibiting the CENP-E from walking in vitro and inhibiting the advance of chromosomes in a mitotic phase to avoid arrangement faults of laggard chromosomes. The small molecule inhibitors Syntelin have important significance for researching cytobiology, and can lay a foundation for developing novel chemotherapeutics due to an effect of controlling tumor cell proliferation.
Description
Technical field
The present invention relates to dynamic some motor protein CENP-E micromolecular inhibitor Syntelin.
Background technology
Cell accurately self-replacation is the important component part of vital movement, and the high conservative property copied is very important in the process of multiplying and living of biological and species.In the process of cellular replication, be included in parent genetic information in karyomit(e) impartial after the motion that experienced by many complexity, distribute to two daughter cells accurately.Cell cycle events is that high-sequential carries out, and the biochemical regulation path that the guarantee cell cycle advances without any confusion is called as " check position " (Checkpoint).
Dynamic point is the polycomponent protein composite structure be positioned on kinetochore.It not only directly maintains chromosomal fibers and is connected with chromosomal, and also regulate and control Time-space serial and the fidelity of chromosome movement and chromosome segregation, this signal path is called as " spindle body check position " (Spindle Checkpoint) simultaneously.The generation causing aneuploid and chromosome instability in reproduction process of cell out of control of spindle body check position, and generation and the development of tumour may be participated in.But up to now, the protein effect network of spindle body check position signal path and the molecular mechanism of information stream transmission thereof still do not understand.
Dynamic some motor protein CENP-E (Centromere-Associated Protein E) is a molecular weight is the kinetochore protein of 312kDa, it contains one and is positioned at the similar motor territory of kinesin of N end and comprises the coiled-coil structural domain of 1069 amino-acid residues, and overall length is 2701 amino acid.CENP-E is the motor protein be directly responsible for dynamic point and be connected spindle microtubule, its coordinative role with other spindle body check position albumen, the process of monitoring cell mitogen, but the details of CENP-E monitoring cell mitogen is still rarely known by the people.The disappearance of CENP-E makes spindle body check position inactivation, causes chromosome movement and sepn process to go wrong thus produces chromosome instability phenotype.For this reason, the structure-function dependency of scrutiny spindle body check position modulin CENP-E is a significantly research work.
Summary of the invention
The object of this invention is to provide a kind of dynamic some motor protein CENP-E micromolecular inhibitor Syntelin.
CENP-E inhibitor provided by the invention, name is called Syntelin, derives from synthetic.Syntelin has the function and karyomit(e) advancing at m period that suppress CENP-E motor protein external walking, causes rear stagnant chromosomal ordered failure, its general structure such as formula compound shown in I or formula II general structure,
In described formula I and formula II general structure, R
1and R
2all be selected from following radicals any one: the alkyl of C1-C6, alkane thiazolinyl, aryl, cycloalkyl and cycloalkenyl;
R
3for aryl, containing substituent aryl, quinary heterocyclic radical or hexa-member heterocycle base;
X is O, NR
4, S or CHR
5;
Y is O, NR
4, S or CHR
6;
In described X and Y, described R
4, R
5, R
6all be selected from alkyl, alkane thiazolinyl and carbalkoxy any one;
Z be selected from following group any one:
In described formula I and formula II general structure, R
1and R
2be methyl or phenyl;
Described R
3for phenyl or
Described X is O, NH, NCH
2cH
2cH
3or S;
Described Y is O or S; Described Z is-COOH.
Shown in described formula I general structure, compound is specially compound shown in formula III-Shi VI and formula XI,
Compound shown in described formula II general structure is compound shown in formula VII-formula X and formula XII,
The method preparing aforesaid compound provided by the invention, comprises the steps:
Compound shown in formula XIII, midbody compound and alkali are carried out back flow reaction in organic solvent, reacts complete and obtain described compound;
In described formula XIII, R
1and R
2all be selected from following radicals any one: the alkyl of C1-C6, alkane thiazolinyl, aryl, cycloalkyl and cycloalkenyl.
In the method, in described formula XIII, R
1and R
2for methyl or phenyl; Described midbody compound be selected from compound shown in formula XIV-formula XVII any one:
Described organic solvent is tetrahydrofuran (THF).
The amount ratio of compound shown in described formula XIII, midbody compound, described alkali and described organic solvent is 1mmol: 1.1mmol: 2mmol: 10ml.
The described method preparing compound, also comprises the steps: after completion of the reaction described, dissolves after reaction system being cooled with chloroform, use water and saturated common salt water washing more successively, after drying, carry out recrystallization with the mixed solution of Virahol and methylene dichloride composition, obtain described compound.
The aforementioned X of preparation provided by the invention is NCH
2cH
2cH
3formula I or formula II shown in the method for compound, comprise the steps:
Shown in the formula I being NH by X or formula II, compound, halogenopropane and alkali carry out back flow reaction in organic solvent, react that complete to obtain described X be NCH
2cH
2cH
3formula I or formula II shown in compound.
In the method, described halogenopropane is N-PROPYLE BROMIDE; Described organic solvent is tetrahydrofuran (THF); Described alkali is salt of wormwood.The amount ratio of compound, halogenopropane, alkali and organic solvent shown in the formula I that described X is NH or formula II is 1mmol: 1.1mmol: 2mmol: 10ml.
Described preparation X is NCH
2cH
2cH
3formula I or formula II shown in the method for compound, also comprise the steps: after completion of the reaction described, dissolve with chloroform after reaction system is cooled, use water and saturated common salt water washing more successively, after drying, carry out recrystallization with the mixed solution of Virahol and methylene dichloride composition, obtaining described X is NCH
2cH
2cH
3formula I or formula II shown in compound.
The organic micromolecule compound driving territory to be combined with CENP-E motor provided by the invention, it can suppress the walking of CENP-E motor on microtubule after being combined with CENP-E, but do not affect the interaction of itself and microtubule, when this compound adds the function that can enter Carbazole alkaloid CENP-E in cell culture medium, chromosome dyad align-err is caused also to maintain the activity of spindle body check position for a long time.
Electronic microscope photos finds that the karyomit(e) of CENP-E micromolecular inhibitor process cell often forms Syntelin and connects (Syntelin connect refer to connect same karyomit(e) sister move spindle microtubule a little from same pole).This phenotype consistent with the phenotype that CENP-E silenced cell embodies (Yao et al., 2000).Lower due to CENP-E function and occur Syntelin chromosomal phenotype, therefore name CENP-E micromolecular inhibitor is Syntelin.
Syntelin specificity suppresses the activity of motor kinesin CENP-E, and its external half effective inhibition concentration is 0.16 μM.Syntelin can wash-out to the restraining effect of CENP-E, and the cell after wash-out can be successfully completed mitotic division, and Syntelin will be very effective instrument medicine for this reason.Utilize Syntelin to the suppression of CENP-E, thus functional protein (group) transport of interference CENP-E mediation and location, immunohistochemical experiment shows that the disturbing influence of CENP-E motor function phosphoprotein phosphatase (PP1 γ) is in the location of dynamic point and subsequently to the dephosphorylation of phosphorylated substrate.Because the dephosphorylized of kinetochore protein is obstructed, cell mitogen spindle body check position is caused to be in active state.Above-mentioned experimental result shows: CENP-E passes through the silence (Silence) of the location regulating cell mitotic spindle check position of modulin Phosphoric acid esterase PP1 γ, thus the anaphase that cell being entered (Anaphase).CENP-E micromolecular inhibitor Syntelin of the present invention will play a significant role in RESEARCH ON CELL-BIOLOGY, and the development that effect of simultaneously its modulate tumor cell proliferation can be new chemotherapeutic drugs lays the foundation.
Accompanying drawing explanation
Fig. 1 is carbon-13 nmr spectra (A) and nitrogen spectrum (B) that embodiment 1 prepares gained target compound.
Fig. 2 is the therapeutic action of Syntelin to Experimental mammary carcinoma.Wherein, A is the result after modeling before administration; B is the administration result of the 10th day, and B figure is DMSO control group, paclitaxel treatment group and syntelin treatment group from left to right successively.
Fig. 3 is the fluorescence activity change of luciferase before and after Syntelin treatment.
Fig. 4 is the restraining effect that Syntelin walks to CENP-E motor protein.Wherein, first row is control (DMSO) group, and second row is Syntelin group.
Fig. 5 is the phenotype analytical of Syntelin to cell mitogen.Wherein, A is the cell mitogen phenotype of DMSO control group (left side) and Syntelin group (right side); The phenotype that B embodies through RNA silence for CENP-E, the left side is Scramble group, and the right is CENP-E SiRNA group; C is the statistical study scheme of CENP-E afunction; D is chromosomal space distribution situation under various processing mode (X-coordinate is the distribution of limit, and ordinate zou is centric per-cent).
Fig. 6 is the impact that Syntelin connects karyomit(e) spindle microtubule.Wherein, A is DMSO group; B is syntelin; C is the electron microscopic section result of syntelin cell; D is the observations of high power; E is the schematic diagram of Syntelin mechanism of action.
Fig. 7 is the impact of Syntelin on cell mitogen dynamic process.Wherein, A is the viable cell experiment flow figure affected cell mitogen for studying syntelin; B is the Real Time Observation result of Hela cell by prometaphase to the later stage of DMSO process, and the green in figure is that EGFP-H2B is used to indicate chromosomal position, and that red is mCherry-tubulin, for characterizing the structure situation of spindle body; C is the observations of Hela cell by the prometaphase in latter 2 hours of syntelin process.Arrow indicates the karyomit(e) do not arranged; D is the reversible viable cell experiment flow figure for studying syntelin drug treating; E is that the karyomit(e) do not arranged after syntelin washes away by diagram from cell achieves the arrangement task arriving equatorial plate subsequently gradually; F is that syntelin is to chromosome movement influencing mechanism schematic diagram.
Fig. 8 is the positioning effects of Syntelin to phosphoprotein phosphatase PP1 γ.Wherein, Fig. 8 A represents DMSO group and syntelin treatment group result; Fig. 8 B scramble siRNA group and CENP-E siRNA group result.Often group has 2 width figure, and last width is the double-colored location of CENP-E (redness) and PP1 γ (green), and a rear width is the three look location of CENP-E (redness), PP1 γ (green) and DNA (blueness).
Embodiment
Below in conjunction with specific embodiment, the invention will be further described, but the present invention is not limited to following examples.In following embodiment, if no special instructions, ordinary method is.Compound shown in formula I provided by the invention can obtain according to following synthesis path preparation:
The synthesis of embodiment 1, target compounds of formula VII:
Compound shown in 1mmol 5a, 1.1mmol intermediate formula XV (its synthesized reference document Monatshefte fuer Chemie, 127 (5), 549-555 are added in there-necked flask, 1996), in 10ml THF, 2mmol K2CO3 under stirring, is added, reflux, TLC monitoring, to reacting completely, cools, suction filtration, decompression and solvent recovery, dissolves gained resistates chloroform, washing, saturated common salt is washed, anhydrous sodium sulfate drying.Suction filtration, recycling design, resistates obtains the sterling of formula VII target compound with Virahol/methylene dichloride recrystallization.
Fig. 1 is that the nuclear-magnetism of sterling formula VII compound (called after Syntelin) detects spectrogram, and A is carbon spectrum, and B is nitrogen spectrum.As seen from the figure, this compound structure is correct, is compound shown in formula VII.
Fig. 1 is that the nuclear-magnetism of sterling formula VII compound (called after Syntelin) detects spectrogram, and A is carbon spectrum, and B is nitrogen spectrum.As seen from the figure, this compound structure is correct, is compound shown in formula VII.
Wherein, compound 5a prepares in accordance with the following steps and obtains:
1) synthesis of intermediate 1a:
0.5mol pimelinketone, 1000ml ethanol is added in round-bottomed flask, 0.5mol ethyl cyanoacetate, 0.5mol sulphur powder, 0.5mol diethylamine is added successively under stirring, after stirring at room temperature 30min, be heated to 50 DEG C, TLC monitoring is to reacting end, be cooled to room temperature, in reaction mixture impouring 3000ml water, a large amount of solid is had to separate out, suction filtration, filtration cakes torrefaction obtains intermediate 1a, is directly used in next step reaction.
2) synthesis of intermediate 2a, 3a:
0.4mol 1a, 1000ml anhydrous methylene chloride is placed in round-bottomed flask; vigorous stirring under room temperature; slowly instill wherein under the 200ml anhydrous methylene chloride solution nitrogen protection of 0.44mol Sulfuryl chloride isocyanate; dropwise; stirring at room temperature is to reacting completely; evaporated under reduced pressure methylene dichloride, obtains yellow solid 2a crude product.In reaction flask, add 2000ml 5%KOH solution, be heated with stirring to 90 DEG C, TLC monitoring is to reacting end, and be cooled to room temperature, suction filtration, filtration cakes torrefaction obtains intermediate 3a.
3) synthesis of intermediate 4a:
The 3a 0.2mol obtained by previous step, excessive phosphorus oxychloride (500ml) and DMF (40ml) reflux 5h.Reaction solution concentrating under reduced pressure is obtained the black material of dark brown colour cast, ice bath separates out a large amount of dark brown deposit.Suction filtration obtains yellow solid, dissolves with trichloromethane.Suction filtration removing insolubles again, filtrate is washed with 5% sodium hydrogen carbonate solution, is washed, and merges organic layer, adds appropriate decolorizing with activated carbon after anhydrous sodium sulfate drying, concentrated.Column chromatography (petrol ether/ethyl acetate=5: 1) obtain beige solid 4a.
4) synthesis of intermediate 5a:
4a 0.1mol, tetrahydrofuran (THF) 300ml that previous step is obtained drop into pressure cooker, and pass into ammonia, room temperature places 8 hours.The crude product filtered, with 95% ethyl alcohol recrystallization, obtains white plates crystal 5a.
The synthesis of embodiment 2, target compound formula III:
(its synthesized reference document Bioorganic & Medicinal Chemistry Letters 16 (17) of compound shown in 1mmol 5b, 1.1mmol intermediate formula XIV is added in there-necked flask, 4444-4449,2006), in 10ml THF, under stirring, add 2mmol K
2cO
3, reflux, TLC monitoring is to reacting completely, and cooling, suction filtration, decompression and solvent recovery, dissolves gained resistates chloroform, washing, and saturated common salt is washed, anhydrous sodium sulfate drying.Suction filtration, recycling design, resistates obtains the sterling of target compound shown in formula III with Virahol/methylene dichloride recrystallization.
Wherein, compound 5b prepares in accordance with the following steps and obtains:
1) synthesis of intermediate 1b:
The preparation method of 1a compound in synthesis step reference example 1.
2) synthesis of intermediate 2b, 3b:
The preparation method of 2a and 3a compound in synthesis step reference example 1.
3) synthesis of intermediate 4b:
The preparation method of 4a compound in synthesis step reference example 1.
4) synthesis of intermediate 5b:
The preparation method of 5a compound in synthesis step reference example 1.
The synthesis of embodiment 3, target compounds of formula VIII:
Add compound shown in 1mmol 5a, 1.1mmol intermediate formula XV (its synthesized reference document Monatshefte fuer Chemie, 127 (5), 549-555,1996) in there-necked flask, in 10ml THF, under stirring, add 2mmol K
2cO
3, reflux, TLC monitoring is to reacting completely, and cooling, suction filtration, decompression and solvent recovery, dissolves gained resistates chloroform, washing, and saturated common salt is washed, anhydrous sodium sulfate drying.Suction filtration, recycling design, resistates obtains the sterling of target compounds of formula VIII with Virahol/methylene dichloride recrystallization.
The synthesis of embodiment 4, target compounds of formula IV:
Add compound shown in 1mmol 5b, 1.1mmol intermediate formula XV (its synthesized reference document Monatshefte fuer Chemie, 127 (5), 549-555,1996) in there-necked flask, in 10ml THF, under stirring, add 2mmol K
2cO
3, reflux, TLC monitoring is to reacting completely, and cooling, suction filtration, decompression and solvent recovery, dissolves gained resistates chloroform, washing, and saturated common salt is washed, anhydrous sodium sulfate drying.Suction filtration, recycling design, resistates obtains the sterling of target compounds of formula IV with Virahol/methylene dichloride recrystallization.
The synthesis of embodiment 5, target compounds of formula IX:
(its synthesized reference document Bioorganic & Medicinal Chemistry Letters 16 (17) of compound shown in 1mmol 5a, 1.1mmol intermediate formula XVI is added in there-necked flask, 4444-4449,2006), in 10ml THF, under stirring, add 2mmol K
2cO
3, reflux, TLC monitoring is to reacting completely, and cooling, suction filtration, decompression and solvent recovery, dissolves gained resistates chloroform, washing, and saturated common salt is washed, anhydrous sodium sulfate drying.Suction filtration, recycling design, resistates obtains the sterling of target compounds of formula IX with Virahol/methylene dichloride recrystallization.
The synthesis of embodiment 6, target compounds of formula V:
(its synthesized reference document Bioorganic & Medicinal Chemistry Letters 16 (17) of compound shown in 1mmol 5b, 1.1mmol intermediate formula XVI is added in there-necked flask, 4444-4449,2006), in 10ml THF, under stirring, add 2mmol K
2cO
3, reflux, TLC monitoring is to reacting completely, and cooling, suction filtration, decompression and solvent recovery, dissolves gained resistates chloroform, washing, and saturated common salt is washed, anhydrous sodium sulfate drying.Suction filtration, recycling design, resistates obtains the sterling of target compounds of formula V with Virahol/methylene dichloride recrystallization.
The synthesis of embodiment 7, target compounds of formula XII:
(its synthesized reference document Annales Universitatis Mariae Curie-Sklodowska of compound shown in 1mmol 5a, 1.1mmol intermediate formula XVII is added in there-necked flask, Sectio AA:Physica et Chemia, 31-32,247-55; 1980), in 10ml THF, 2mmol K under stirring, is added
2cO
3, reflux, TLC monitoring is to reacting completely, and cooling, suction filtration, decompression and solvent recovery, dissolves gained resistates chloroform, washing, and saturated common salt is washed, anhydrous sodium sulfate drying.Suction filtration, recycling design, resistates obtains the sterling of target compounds of formula XII with Virahol/methylene dichloride recrystallization.
The synthesis of embodiment 8, target compounds of formula XI:
(its synthesized reference document Annales Universitatis Mariae Curie-Sklodowska of compound shown in 1mmol 5b, 1.1mmol intermediate formula XVII is added in there-necked flask, Sectio AA:Physica et Chemia, 31-32,247-55; 1980), in 10ml THF, 2mmol K under stirring, is added
2cO
3, reflux, TLC monitoring is to reacting completely, and cooling, suction filtration, decompression and solvent recovery, dissolves gained resistates chloroform, washing, and saturated common salt is washed, anhydrous sodium sulfate drying.Suction filtration, recycling design, resistates obtains the sterling of target compounds of formula XI with Virahol/methylene dichloride recrystallization.
The synthesis of embodiment 9, target compounds of formula X:
Add 1mmol embodiment 5 in there-necked flask and prepare compound shown in gained formula XI, 1.1mmol N-PROPYLE BROMIDE, in 10ml THF, under stirring, add 2mmol K
2cO
3, reflux, TLC monitoring is to reacting completely, and cooling, suction filtration, decompression and solvent recovery, dissolves gained resistates chloroform, washing, and saturated common salt is washed, anhydrous sodium sulfate drying.Suction filtration, recycling design, resistates obtains the sterling of target compounds of formula X with Virahol/methylene dichloride recrystallization.
The synthesis of embodiment 10, target compounds of formula VI:
Add 1mmol embodiment 6 in there-necked flask and prepare compound shown in gained formula V, 1.1mmol N-PROPYLE BROMIDE, in 10ml THF, under stirring, add 2mmol K
2cO
3, reflux, TLC monitoring is to reacting completely, and cooling, suction filtration, decompression and solvent recovery, dissolves gained resistates chloroform, washing, and saturated common salt is washed, anhydrous sodium sulfate drying.Suction filtration, recycling design, resistates obtains the sterling of target compounds of formula VI with Virahol/methylene dichloride recrystallization.
Following embodiment 11-12 Syntelin used is compound shown in formula VII that embodiment 1 prepares.
Embodiment 11, Syntelin suppress the growth of breast cancer cell
1, experimental procedure
Modeling: the encoding gene of luciferase (is imported the reconstitution cell of the stably express luciferase that human breast cancer cell MDA-MB-231 obtains by the mammary cancer MDA-MB231 cell of tail vein injection stably express luciferase by immune deficiency NOD/SCID mouse (Jackson Laboratory), according to KangY, Siegel PM, Shu W, Drobniak M, Kakonen SM, Cord ó n-Cardo C, Guise TA, Massagu é J.A multigenic program mediating breast cancer metastasis to bone.Cancer Cell.2003Jun, the method of 3 (6): 537-49 documents builds (please provide the document of this cell construction method of description of Joan Massague ' doctor)) modeling.Every mouse mainline 2 × 10
5the MDA-MB231 cell of individual stably express LUC.
Treatment: modeling success after (namely after tumor inoculation after 3-4 week when tumour reaches 100mm
3size) 24 mouse, be divided into 3 groups, be respectively syntelin treatment group, paclitaxel treatment group and control group.
Syntelin and taxol use DMSO (dimethyl sulfoxide (DMSO)) to dissolve for intravenous injection respectively.
Every mouse of syntelin treatment group is respectively by DMSO solution (the 30mg syntelin/kg body weight of intravenous injection syntelin, injection in every three days once), every mouse of paclitaxel treatment group is respectively by the DMSO solution (30mg taxol/kg body weight) of intravenous injection taxol, and every mouse of control group is respectively by the isopyknic DMSO of intravenous injection.The result for the treatment of of drug on tumor is determined by biodiversity resources instrument every other day.
2, experimental result
The success of above-mentioned injection detects by bioluminescent detection instrument IVIS Imaging System.
Make film step results: (tumor region is high-visible in biodiversity resources instrument in the mammary cancer MDA-MB231 injection rear modeling success in 4 weeks of stably express luciferase; See Fig. 2 A).
Therapeutic progresses result: as shown in Figure 2 B, syntelin and taxol all can suppress the growth of mammary cancer MDA-MB231 cell to the administration result of the 10th day.
After testing, as shown in Figure 3, fluorescence activity all significantly reduces the fluorescence activity of the luciferase after above-mentioned three groups of treatments after Syntelin and administering paclitaxel compared with the control.
Embodiment 12, Syntelin are by suppressing CENP-E motor protein active thus suppressing mitotic division to be carried out
One, Syntelin impact that ira vitro tube is walked
(1), experimental principle
In view of the energy drives microtubule based motor that CENP-E motor protein utilizes hydrolysising ATP to produce, the assessment that upper research CENP-E motor activity directly perceived is learned in experiment is that microtubule moves experiment [Wood et al., 1997].For this reason, the micromolecular compound of CENP-E is directly suppressed will to be the bonding force suppressing the locomotivity of microtubule and do not disturb motor protein and microtubule.
(2), experimental technique and step
Ira vitro tube walking experiment carries out in the space of a sample chamber formed between a slice slide glass and cover glass be bonded together by a pair double sticky tape.First antibody (the Monoclonal Anti-poly-histidine antibody produced in mouse clone HIS-1 of identification 6 × histidine label is used, Sigma company, H-1029) motor portion of the CENP-E albumen containing this label is coupled at surface of glass slide in sample chamber.Then add the taxol of negative terminal highlight mark stable, the microtubule of rhodamine mark, ATP and DMSO (as negative control) or syntelin medicine.Finally Real Time Observation and the motion conditions recording surface of glass slide microtubule in sample chamber under the fluorescent microscope that deconvolutes.What present in contrast (control) and syntelin treatment group is to the observations (Fig. 4) of surface of glass slide specific region in sample chamber every 30 seconds respectively in testing separately.
There is the positive end of the microtubule slided in the Arabic numerals sentinel in Fig. 4, white filled arrows then indicates the microtubule do not moved.The length representative physical length of scale 5 microns.
Fig. 4 shows, the sliding microtubule that DMSO negative control group (Control): CENP-E drives, and the microtubule being labeled as 1 has slided 7.9 microns in 90 seconds; The microtubule being labeled as 2 started the microtubule always static with in the 30th second to be separated, and the slip that went ahead in ensuing 60 seconds, all mean motion speed that the microtubule slided occurs observed are 5.3 ± 1.7 [mu (n=49).Syntelin group: 200nM syntelin is on the impact of microtubule based motor.The microtubule being labeled as 1 0.1 micron 90 seconds slides forwards.
The concrete steps of ira vitro tube walking experiment are as follows:
1, the process of cover glass: cover glass is placed on cold 0.5M salt acid soak 12 hours, then uses washed with de-ionized water, gets rid of remaining hydrochloric acid, finally preserves in ethanol.During use, slide is taken out from ethanol, clean with deionized water rinsing, dry in atmosphere.
2, the process of slide glass: soaked in deionized water by slide glass, then ultrasonic removal surface impurity, cleans and dry at air.
3, the assembling of sample chamber: a slice slide glass and a slice cover glass are bonded together with two double sticky tapes.Article two, the distance between adhesive tape determines the volume of formed sample chamber, and the volume of general sample chamber is to be advisable between 10 μ l to 20 μ l.
4, by BRB80 solution (80mM PIPES [pH 6.8], 1mMEGTA, the 1mMMgCl of the antibody precooling of identification 6 × histidine label
2) dilution 10 times, in sample chamber, then add 10 μ l antibody diluents, incubated at room 1 minute.
5, add 10 μ l confining liquids (0.25mg/ml casein protein solution) at the side opening part of sample chamber slowly sample chamber to be tilted to liquid and flowed out by the opening part of opposite side, and effluent liquid filter paper is blotted.Repeat loading four times.Incubated at room 5 minutes.
6, motor protein solution (namely containing fusion rotein 5 μ g/ml, solvent is DMSO) totally 50 μ l are added according to the mode in step 5.Incubated at room 5 minutes.
7, dividing two groups to test, is DMSO negative control group (Control) and syntelin drug treating group respectively.
DMSO negative control group (Control): the solution 50 μ l containing 10 μMs of taxols and 1mM ATP adding the BRB80 solution preparation with preheating.
Syntelin group: the solution 50 μ l containing 10 μMs of taxols, 1mM ATP and 200nMsyntelin adding the BRB80 solution preparation with preheating.
8, the solution containing 10 μMs of taxol, 1mM ATP and 3 μ g/ml rhodamines mark microtubule (this microtubule is the tubulin of the Cytoskeleton company of purchased from American) of the BRB80 solution preparation with preheating is added.
9, then the both sides scotch tape of sample chamber opening is sealed, and the motion conditions of horse back Real Time Observation surface of glass slide microtubule on fluorescent microscope.
In above-mentioned steps 6, the preparation method of fusion rotein (namely CENP-E motor protein drives territory (the 1-473 position of sequence 1)) is as follows:
DNA fragmentation shown in sequence 2 in preparation sequence table (in this DNA fragmentation polynucleotide sequence 1 1-473 position shown in albumen), then insert between Nde1 and Xho1 on pET21a (holding 6X-histidine containing C-) carrier, obtain plasmid pET21a-CENP-E-N473.GFP gene shown in sequence 3 in preparation sequence table, accesses the Xho1 site of above-mentioned pET21a-CENP-E-N473 plasmid, obtains plasmid pET21a-CENP-E-N473-GFP with single endonuclease digestion method.
The recombinant expression vector pET21a-CENP-E-N473-GFP built is proceeded to the expression carrying out albumen in E.coli Rosetta (DE3) pLys bacterial strain, and carry out the purifying of albumen with Ni-NTA resin (Qiagen company).The eluant solution of albumen on resin containing 250mM imidazole gets off and carries out dialysis 50mM MOPS (pH 7.0), 250mM KCl, 0.5mMEGTA, 2mM MgCl
2, in 10%glycerol.The concrete steps of protein expression and purification are as follows:
1, plasmid pET21a-CENP-E-N473-GFP is converted in E.coli Rosetta (DE3) pLys competent cell, and thalline is coated on the LB flat board containing 100ug/ml penbritin and 34ug/ml paraxin, be cultured to mono-clonal bacterium colony at 37 DEG C and occur.
2, picking mono-clonal bacterium colony be inoculated in the LB liquid nutrient medium of 5ml sterilising treatment and (add penbritin and the paraxin of above-mentioned concentration simultaneously), 37 DEG C are shaken bacterium and spend the night.
3, by the bacterium liquid of overnight incubation with 1: 100 ratio be inoculated in the 500ml LB substratum of sterilising treatment and (add penbritin and the paraxin of above-mentioned concentration simultaneously), 37 DEG C are shaken bacterium to OD
580when reaching 0.5, add the IPTG that final concentration is 0.1mM, and then at 16 DEG C inducible protein express 16 hours.
4, after induction terminates, 5,000rpm collects thalline in centrifugal 5 minutes.
5, abandon supernatant, with the resuspended thalline of the cracked solution 20ml of precooling, then adopt pressure breaking method cracking somatic cells, release albumen.
6, at 4 DEG C 12,000rpm centrifugal 30 minutes.
7, supernatant liquor is transferred in a clean albumen incubation tube, then with 0.5ml at 4 DEG C, hatch 2 hours with the Ni-NTA resin that cracked solution is equilibrated in advance.Collection obtains albumen shown in the 1-473 position with sequence 1 in histidine-tagged sequence table, and this albumen is called fusion rotein.
Two, Syntelin is on mitotic impact
1, Syntelin is to the phenotype analytical of cell mitogen
1) experimental procedure
Arrange following four groups, the 1st group is DMSO control group; 2nd group is syntelin group; 3rd group is Scramble group, i.e. negative control siRNA group, and the sequence of the siRNA of institute's transfection is 5 '-AAAACCAUCAUACCAGAGACA-3 '; 4th group is the siRNA group for CENP-E, and the sequence of the siRNA of institute's transfection is 5 '-AAACACUUACUGCUCUCCAGUUU-3 '.
With the DMSO solution [syntelin group] containing 1 μM of syntelin or isopyknic DMSO[DMSO control group] process HeLa cell (Invitrogen company) after 1 hour, carry out immunohistochemical methods after fixing through 4% formaldehyde, punch and closing.In order to verify the phenotype after the suppression of CENP-E motor function, another two groups of experiments are transfection siRNA and scramble sequence control for CENP-E.4th group is changed liquid for the siRNA of CENP-E and the liposome transfection growth HeLa cell on the cover slip of 2 μ l Lipofectamine2000 (Invitrogen Inc.) after 4 hours containing 50nM with 400 μ l Opti-MEM (Invitrogen Inc.).3rd group compared with the 4th group, only the siRNA for CENP-E is replaced with negative control siRNA, all the other treatment processs are all identical.Transfection was fixed through 4% formaldehyde after 36 hours, punching and carry out after closing adopting according to the method for such as Publication about Document carrying out immunohistochemical methods for microtubule and a dynamic some marker protein ACA: Yao, X., Anderson, K.L., and Cleveland, D.W. (1997) .The microtubule-dependent motor centromere-associated protein E (CENP-E) is an integral component of kinetochore corona fibers that link centromeres to spindle microtubules.J Cell Biol139, 435-447).
2) experimental result
As shown in Figure 5.In Fig. 5 A and Fig. 5 B, the microtubule of m period cell is labeled as green, and dynamic point is for red, and karyomit(e) is blue.Scale represents physical length 5 μm.
It is the dyeing location phenotype of above-mentioned three kinds of structures of a normal cell (DMSO control group) in the figure on Fig. 5 A left side.The right is the phenotype of the prometaphase cell of exception after the 1 μM of syntelin process of a use, arrow mark be the karyomit(e) of erroneous arrangement.
The phenotype that Fig. 5 B embodies through RNA silence for CENP-E.The phenotype of the m period cell of the left side Scramble group negative control SiRNA that has been transfection.The right CENP-E SiRNA group has been transfection for the location phenotype of three kinds of structures in cell after the SiRNA of CENP-E.Arrow mark be the karyomit(e) of erroneous arrangement.
Fig. 5 C is the statistical study of CENP-E afunction.Illustrate point dynamic on karyomit(e) axial apart from the distance measurement method of a nearest pole and the normalized mode of data standard along the two poles of the earth.
Fig. 5 D is chromosomal space distribution situation under the various cell processing mode that obtain by measurement and the treatment process of Fig. 5 C.Illustrate relative to two kinds of negative control cases, two kinds of exceptions that all can clearly cause karyomit(e) to distribute between koilocytosis to the method (adding syntelin or siRNA transfection) of CENP-E function interference, illustrate that syntelin can disturb the motor function of CENP-E as the siRNA of CENP-E.
2, Syntelin impact that spindle microtubule is connected karyomit(e)
The schematic diagram of Syntelin mechanism of action as illustrated in fig. 6e.
At deepfreeze cell, after removing the microtubule of the non-dynamic connection of depolymerization, (concrete step HeLa cell is put into 4 degree of refrigerator and cooled process fix (Yao again after 10 minutes, X., Anderson, K.L., and Cleveland, D.W. (1997) .The microtubule-dependent motor centromere-associated protein E (CENP-E) is an integral component of kinetochore corona fibers that link centromeres to spindle microtubules.J Cell Biol 139, 435-447), to microtubule (green), dynamic point (redness) and karyomit(e) (blueness) dye and respectively at the basis of microscopic observation DMSO (Normal group that deconvolutes, Fig. 6 A) or 1 μM of syntelin solution (dissolve syntelin with DMSO, 1 μM is diluted to DMEM substratum) (syntelin treatment group, Fig. 6 B) on the HeLa cell process impact of 30 minutes.The part that corner is amplified shows the connection of dynamic point-microtubule.Result as shown in Fig. 6 A and Fig. 6 B (scale represents physical length 5 μm), as can be seen from the figure amplified: the cell chromosome proper alignment in Normal group is under the line on plate, and its dynamic point becomes equalization to be bi-directionally connected with the microtubule from two ends.And the karyomit(e) of syntelin treatment group cell is dispersed near centrosome substantially in unidirectional syntelic connection.
After above-mentioned 1 μM of syntelin process, the electron microscopic section observations of cell is as shown in Fig. 6 C and D.Fig. 6 C is the observations of the structure to whole cell of low magnification.Be arranged in except great majority except the karyomit(e) on equatorial plate, clearly can observe some and be positioned at karyomit(e) near the two poles of the earth in electron microscopic picture.The observations corresponding to the high power in the picture rectangle frame of the left side of Fig. 6 D.Arrow instruction be from microtubule and two on item chromosome of same centriole (starlike sign flag) dynamic put all to establish be connected.Scale in the figure of the left side represents physical length 5 μm, and the scale in the figure of the right represents physical length 1 μm.
3, Syntelin is on the impact of cell mitogen dynamic process
Syntelin to chromosome movement influencing mechanism schematic diagram as shown in Figure 7 F.The viable cell experiment flow figure that research syntelin affects cell mitogen as shown in Figure 7 A.Concrete steps first use 5 μMs of monastrol HeLa cells Synchronous in the prometaphase, then cell culture fluid Opti-MEM (Invitrogen) is used to wash three times and the syntelin solution adding 1 μM (dissolves syntelin with DMSO, 1 μM is diluted to or isopyknic DMSO carries out viable cell observation (Liu with Opti-MEM substratum, J., Wang, Z., Jiang, K., Zhang, L., Zhao, L., Hua, S., Yan, F, Yang, Y, Wang, D., Fu, C., et al. (2009) .PRC 1cooperates with CLASP 1to organize central spindle plasticity in mitosis.J Biol Chem 284, 23059-23071.).
Result is as shown in Fig. 7 B and C.B is the Real Time Observation result of Hela cell by prometaphase to the later stage of DMSO process, and the green in figure is that EGFP-H2B is used to indicate chromosomal position, and that red is mCherry-tubulin, for characterizing the structure situation of spindle body; C is the observations of Hela cell by the prometaphase in latter 2 hours of syntelin process, and arrow indicates the karyomit(e) do not arranged.Describing the motor activity suppressing CENP-E hinders karyomit(e) to the gathering of equatorial plate.
Reversible viable cell experiment flow figure of research syntelin drug treating as illustrated in fig. 7d.Concrete steps are the syntelin solution-treated HeLa cell of the monastrol of 5 μMs and above-mentioned 1 μM 60 minutes, then wash three times with above-mentioned cell culture fluid and carry out viable cell observation.
As seen in figure 7e, the karyomit(e) do not arranged after being washed away from cell by syntelin achieves the arrangement task arriving equatorial plate to result subsequently gradually.
4, Syntelin is to the positioning effects of phosphoprotein phosphatase PP1 γ
1) experimental procedure
The Syntelin of 1 μM and the DMSO process HeLa cell of equal volume, after 60 minutes, carry out adopting antibody for Phosphoric acid esterase PP1 γ carry out immunohistochemical methods after fixing, punch and closing through 4% formaldehyde.Concrete steps and method ask for an interview Ding et al., 2010 (Ding X, Yan F, Yao P, Yang Z, Wan W, Wang X, Liu J, Gao X, Abrieu A, Zhu T, Zhang J, Dou Z, Yao X. (2010) .Probing CENP-E function in chromosome dynamics using small molecule inhibitor syntelin.Cell Res.20,1386-9).
2) experimental result
Result as shown in Figure 8.
Fig. 8 A represents DMSO group and syntelin treatment group result.In control treatment (DMSO) group, Phosphoric acid esterase PP1 γ (green) and CENP-E (redness) are positioned dynamic point jointly.The part that corner is amplified shows the common positioning scenarios of dynamic point.Scale represents physical length 5 μm.But as (1 μM of for 30min) after syntelin process, Phosphoric acid esterase PP1 γ (green) and CENP-E (redness) signal fade away CENP-E (redness).The part that corner is amplified shows the situation that Phosphoric acid esterase PP1 γ and CENP-E reduces at dynamic point location, and prompting suppresses CENP-E motor activity that Phosphoric acid esterase PP1 γ can be suppressed in the location of dynamic point.Scale represents physical length 5 μm.
Fig. 8 B scramble siRNA group and CENP-E siRNA group result.In contrast siRNA (scramble siRNA) treatment group, Phosphoric acid esterase PP1 γ (green) and CENP-E (redness) are positioned dynamic point jointly.The part that corner is amplified shows the common positioning scenarios of dynamic point.Scale represents physical length 5 μm.As (1 μM of for 30min) after CENP-E siRNA process, Phosphoric acid esterase PP1 γ (green) and CENP-E (redness) signal fade away CENP-E (redness).The part that corner is amplified shows the situation that Phosphoric acid esterase PP1 γ and CENP-E reduces at dynamic point location, illustrates that Phosphoric acid esterase PP1 γ depends on CENP-E in the location of dynamic point.Scale represents physical length 5 μm.The function (sliding microtubule that treatment tumor cell proliferation, T suppression cell mitotic division, suppression motor protein drive) that embodiment 2-10 prepares gained target compound prepares the function there was no significant difference of gained target compound with embodiment 1.
Claims (7)
1. compound shown in formula I or formula II general structure,
Wherein, compound shown in described formula I general structure is compound shown in formula III-Shi VI and formula XI,
Compound shown in described formula II general structure is compound shown in formula VIII-formula X and formula XII,
2. prepare a method for compound shown in formula I general structure described in claim 1, comprise the steps:
Compound shown in formula XIII, midbody compound and alkali are carried out back flow reaction in organic solvent, reacts complete and obtain compound shown in formula I general structure described in described claim 1;
In described formula XIII, R
1for phenyl; R
2for methyl; Described midbody compound be selected from compound shown in formula XIV-formula XVII any one:
Described organic solvent is tetrahydrofuran (THF).
3. method according to claim 2, is characterized in that: the amount ratio of compound shown in described formula XIII, midbody compound, described alkali and described organic solvent is 1mmol:1.1mmol:2mmol:10ml.
4. according to the method in claim 2 or 3, it is characterized in that: the described method preparing compound described in claim 1, also comprise the steps: after completion of the reaction described, dissolve with chloroform after reaction system is cooled, use water and saturated common salt water washing more successively, after drying, carry out recrystallization with the mixed solution of Virahol and methylene dichloride composition, obtain compound described in described claim 1.
5. one kind is prepared X in claim 1 is NCH
2cH
2cH
3formula I or formula II shown in the method for compound, comprise the steps:
Shown in the formula I being NH by X in claim 1 or formula II, compound, halogenopropane and alkali carry out back flow reaction in organic solvent, react that complete to obtain X in described claim 1 be NCH
2cH
2cH
3formula I or formula II shown in compound.
6. method according to claim 5, is characterized in that: described halogenopropane is N-PROPYLE BROMIDE; Described organic solvent is tetrahydrofuran (THF); Described alkali is salt of wormwood; The amount ratio of compound, halogenopropane, alkali and organic solvent shown in the formula I that in described claim 1, X is NH or formula II is 1mmol:1.1mmol:2mmol:10ml.
7. the method according to claim 5 or 6, is characterized in that: in described preparation claim 1, X is NCH
2cH
2cH
3formula I or formula II shown in the method for compound, also comprise the steps: after completion of the reaction described, dissolve with chloroform after reaction system is cooled, use water and saturated common salt water washing more successively, after drying, carry out recrystallization with the mixed solution of Virahol and methylene dichloride composition, obtaining X in described claim 1 is NCH
2cH
2cH
3formula I or formula II shown in compound.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110356727.XA CN102532159B (en) | 2010-11-12 | 2011-11-11 | Small molecule inhibitors Syntelin for centromere-associated protein E (CENP-E) |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010544018 | 2010-11-12 | ||
CN201010544018.X | 2010-11-12 | ||
CN201110356727.XA CN102532159B (en) | 2010-11-12 | 2011-11-11 | Small molecule inhibitors Syntelin for centromere-associated protein E (CENP-E) |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102532159A CN102532159A (en) | 2012-07-04 |
CN102532159B true CN102532159B (en) | 2015-02-11 |
Family
ID=46050342
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180048379.8A Active CN103261205B (en) | 2010-11-12 | 2011-11-11 | Dynamic some motor protein CENP-E micromolecular inhibitor SYNTELIN and application thereof |
CN201110356727.XA Active CN102532159B (en) | 2010-11-12 | 2011-11-11 | Small molecule inhibitors Syntelin for centromere-associated protein E (CENP-E) |
CN2011103567316A Active CN102552274B (en) | 2010-11-12 | 2011-11-11 | Application of moving point motor protein small molecular inhibitor to inhibition of tumor cell proliferation |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180048379.8A Active CN103261205B (en) | 2010-11-12 | 2011-11-11 | Dynamic some motor protein CENP-E micromolecular inhibitor SYNTELIN and application thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011103567316A Active CN102552274B (en) | 2010-11-12 | 2011-11-11 | Application of moving point motor protein small molecular inhibitor to inhibition of tumor cell proliferation |
Country Status (2)
Country | Link |
---|---|
CN (3) | CN103261205B (en) |
WO (1) | WO2012062044A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8933087B2 (en) | 2010-07-23 | 2015-01-13 | President And Fellows Of Harvard College | Tricyclic proteasome activity enhancing compounds |
WO2013112706A1 (en) * | 2012-01-25 | 2013-08-01 | Proteostasis Therapeutics, Inc. | Proteasome activity modulating compounds |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1192142A (en) * | 1995-08-03 | 1998-09-02 | 普罗克特和甘保尔公司 | Use of 1H-1,2,4-triazole derivatives for inhibiting the growth of cancers |
WO2001007436A2 (en) * | 1999-07-28 | 2001-02-01 | Aventis Pharmaceuticals Inc. | Substituted oxoazaheterocyclyl compounds |
CN1291892A (en) * | 1998-01-27 | 2001-04-18 | 阿温蒂斯药物制品公司 | Substituted oxoazaheterocyclyl factor Xa inhibitors |
CN101100472A (en) * | 2001-04-30 | 2008-01-09 | 美国拜尔公司 | 4-amino-5,6-substituted thiopheno [2,3-D] pyrimidines compound and its uses |
US20090163545A1 (en) * | 2007-12-21 | 2009-06-25 | University Of Rochester | Method For Altering The Lifespan Of Eukaryotic Organisms |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6710017B2 (en) * | 2000-02-07 | 2004-03-23 | Avecia, Inc. | Compositions and methods for controlling algae in recirculating water systems |
DE602004021363D1 (en) * | 2003-04-01 | 2009-07-16 | Smithkline Beecham Corp | IMIDAZOTRIAZIN COMPOUNDS FOR THE TREATMENT OF CANCER DISEASES |
CN100391451C (en) * | 2005-04-08 | 2008-06-04 | 中山大学 | Application of cantharidin derivative in preparation of antitumour medicine |
-
2011
- 2011-11-11 CN CN201180048379.8A patent/CN103261205B/en active Active
- 2011-11-11 WO PCT/CN2011/001897 patent/WO2012062044A1/en active Application Filing
- 2011-11-11 CN CN201110356727.XA patent/CN102532159B/en active Active
- 2011-11-11 CN CN2011103567316A patent/CN102552274B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1192142A (en) * | 1995-08-03 | 1998-09-02 | 普罗克特和甘保尔公司 | Use of 1H-1,2,4-triazole derivatives for inhibiting the growth of cancers |
CN1291892A (en) * | 1998-01-27 | 2001-04-18 | 阿温蒂斯药物制品公司 | Substituted oxoazaheterocyclyl factor Xa inhibitors |
WO2001007436A2 (en) * | 1999-07-28 | 2001-02-01 | Aventis Pharmaceuticals Inc. | Substituted oxoazaheterocyclyl compounds |
CN101100472A (en) * | 2001-04-30 | 2008-01-09 | 美国拜尔公司 | 4-amino-5,6-substituted thiopheno [2,3-D] pyrimidines compound and its uses |
US20090163545A1 (en) * | 2007-12-21 | 2009-06-25 | University Of Rochester | Method For Altering The Lifespan Of Eukaryotic Organisms |
Non-Patent Citations (3)
Title |
---|
Chamanlal J. Shishoo,等.Design, synthesis and antihistaminic(H1) activity of some condensed 3-aminopyrimidin-4(3H)-ones.《Eur. J. Med. Chem.》.2000,第35卷(第3期),第351-358页. * |
Maria Modica,等.High Potent and Selective Arylpiperazine Derivatives as Ligands for the 5-HT1A Receptor.《Bioorganic & * |
Medicinal Chemistry Letters》.2000,第10卷(第10期),第1089-1092页. * |
Also Published As
Publication number | Publication date |
---|---|
CN103261205B (en) | 2015-08-19 |
CN102532159A (en) | 2012-07-04 |
CN102552274B (en) | 2013-10-23 |
CN102552274A (en) | 2012-07-11 |
WO2012062044A1 (en) | 2012-05-18 |
CN103261205A (en) | 2013-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Grandane et al. | 6-Substituted sulfocoumarins are selective carbonic anhdydrase IX and XII inhibitors with significant cytotoxicity against colorectal cancer cells | |
Jin et al. | Cyclometalated iridium (III) complexes with imidazo [4, 5-f][1, 10] phenanthroline derivatives for mitochondrial imaging in living cells | |
JP2018528246A (en) | TEAD transcription factor self palmitoylation inhibitor | |
CN107922387A (en) | The heterocycle inhibitor of ERK1 and ERK2 and its application in treatment of cancer | |
CN102532159B (en) | Small molecule inhibitors Syntelin for centromere-associated protein E (CENP-E) | |
Laco et al. | Cardiomyocyte differentiation of pluripotent stem cells with SB203580 analogues correlates with Wnt pathway CK1 inhibition independent of p38 MAPK signaling | |
Zhou et al. | Keto-salicylaldehyde azine: a kind of novel building block for AIEgens and its application in tracking lipid droplets | |
Assiri et al. | Synthesis and anticancer activity of some novel diethyl {(chromonyl/pyrazolyl)[(4-oxo-2-phenyl-quinazolin-3 (4 H)-yl) amino] methyl} phosphonates | |
Huang et al. | Proton donor modulating ESIPT-based fluorescent probes for highly sensitive and selective detection of Cu 2+ | |
Yao et al. | Synthesis, anticancer activity and mechanism of iron chelator derived from 2, 6-diacetylpyridine bis (acylhydrazones) | |
Zhou et al. | Small molecules inhibit STAT3 activation, autophagy, and cancer cell anchorage-independent growth | |
CN112601734A (en) | Oximido naphthoquinone compound and preparation method and application thereof | |
CN113995758B (en) | Application of carbazole-pyrimidine derivative in preparation of antitumor drugs | |
CN110343109B (en) | Dihydropyridone-sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method and application thereof | |
CN107253944A (en) | Tetrahydro benzo thiophene derivant and its purposes in glycogen synthase kinase 3-beta inhibitors are prepared | |
CN113773265A (en) | Fluorescent probe for detecting CYP450, preparation method and application thereof | |
Liu et al. | Improved antiproliferative activities of a new series of 1, 3, 4-thiadiazole derivatives against human leukemia and breast cancer cell lines | |
CN113149980A (en) | Tert-butyloxycarbonyl micromolecule organic compound targeting PUF60, derivative thereof and application thereof | |
Xiang et al. | Synthesis of 2-C-substituted benzothiazoles via a copper-promoted domino condensation/S-arylation/heterocyclization process | |
CN104447681B (en) | Compound for treating cancer and its preparation method and application | |
CN113943264B (en) | Compound for inhibiting formation of G3BP1 stress particles, preparation method and application thereof | |
CN103044350A (en) | Preparation of 1,3,4-oxadiazole compounds and application thereof in anticancer treatment drug | |
KR101731624B1 (en) | Compositions for inducing a cell re-programming | |
CN108484494A (en) | 2- oxo -1,2- dihydropyridine -4- formic acid compounds | |
CN117736135B (en) | Method for site-specific modification of proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: DING XIA Effective date: 20130709 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20130709 Address after: 100097 Beijing city Haidian District landianchang Applicant after: Yao Xuebiao Applicant after: Ding Xia Address before: 100097 Beijing city Haidian District landianchang Applicant before: Yao Xuebiao |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |